Weinhoff Gregory M 4

What Happened Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc (CNTA), had 14,158 shares disposed (withheld) on Feb 1, 2026 at $24.57 each to satisfy tax withholding obligations — proceeds ≈ $347,862. On Feb 2, 2026 he was granted/awarded a total of 154,000 share-equivalents: 31,000 shares (acquisition) and 123,000 RSU-type derivative awards (both reported at $0 intrinsic cost).

Key Details

• Transaction dates: Feb 1, 2026 (tax withholding sale) and Feb 2, 2026 (awards/grants).
• Sale/withholding: 14,158 shares × $24.57 = $347,862 (code F — tax/withholding disposition).
• Grants: 31,000 shares reported as acquired and 123,000 derivative RSUs reported as acquired (both at $0).
• Vesting: The RSUs are subject to vesting — they vest and settle in four equal annual installments, with the first annual vesting on Feb 2, 2027 (footnote). Another footnote notes certain option vesting occurs 1/48th monthly beginning Mar 2, 2026.
• ADS note: Ordinary shares may be represented by American Depositary Shares (each ADS currently equals one Ordinary Share).
• Shares owned after the transactions: not specified in the filing.
• Filing timeliness: Report filed Feb 3, 2026 for Feb 1–2 transactions — appears timely (Form 4 is typically due within two business days).

Context

• The 14,158-share disposal was a tax-withholding event (routine administrative sale) tied to equity awards, not an open-market sell for discretionary cash. The larger 154,000 share-related entries are awards/RSUs that generally vest over time and do not reflect an immediate acquisition of freely tradable shares.